

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

NCT07287644

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	Bluefin Biomedicine, Inc.
Enrollment	210 participants

Key Eligibility Criteria

Inclusion (3)

- Are adults (18 to 75 years) with a diagnosis of hidradenitis suppurativa for at least one year.
- Have moderate to severe disease not well controlled by systemic antibiotic treatment.
- Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.

Exclusion (3)

- Have certain infections or other immune conditions.
- Recently used medications that could interfere with the study.
- Are pregnant or breastfeeding.

Locations (33 total)

Saguaro Dermatology, Phoenix, Arizona, United States
Encino Research Center, Encino, California, United States
Clinical Science Institute, Santa Monica, California, United States
... and 30 more locations